News
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...
Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive ...
In a June 24, 2025, podcast, Goldman Sachs’ Christian Mueller-Glissmann and Alexandra Wilson-Elizondo examined the dynamics ...
Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive ...
Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...
Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver scarring in patients with fatty liver disease in a mid-stage trial.
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis ...
Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis during a key MASH trial. While it helped with MASH resolution and weight ...
GAITHERSBURG, Md. - Altimmune, Inc. (NASDAQ:ALT), whose stock has surged over 13% in the past week according to InvestingPro data, announced Thursday that its Phase 2b trial of pemvidutide for ...
20d
InvestorsHub on MSNAltimmune Shares Slide 37% Despite Hitting Key MASH Trial GoalsAltimmune Inc. (NASDAQ:ALT) saw its stock tumble by 37% after releasing topline data from its Phase 2b IMPACT trial evaluating pemvidutide for the treatment of metabolic dysfunction-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results